Gsk (GSK) Other Accumulated Expenses (2009 - 2026)

Gsk (GSK) has 18 years of Other Accumulated Expenses data on file, last reported at -$818.4 million in Q2 2026.

• For the quarter ending Q2 2026, Other Accumulated Expenses fell 6.69% year-over-year to -$818.4 million; the trailing twelve-month figure through Jun 2026 stood at -$818.4 million (down 6.69% YoY), and the FY2025 full-year result was -$811.4 million, down 7.77% from the prior year.
• Other Accumulated Expenses was -$818.4 million for Q2 2026 at Gsk, down from -$780.6 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of -$40.3 million in Q1 2022 to a low of -$908.1 million in Q3 2025.
• A 5-year average of -$678.3 million and a median of -$695.3 million in 2023 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses surged 95.66% in 2022 and sank 1521.48% in 2023, its largest moves.
• Gsk's Other Accumulated Expenses stood at -$624.0 million in 2022, then gained by 1.54% to -$614.4 million in 2023, then slipped by 23.05% to -$756.0 million in 2024, then retreated by 7.33% to -$811.4 million in 2025, then dropped by 0.87% to -$818.4 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were -$818.4 million in Q2 2026, -$780.6 million in Q1 2026, and -$811.4 million in Q4 2025.